(Reuters) -Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.
The company has revised its 2025 sales forecast upwards to a range of $5.7 billion to $6.1 billion, from the previously projected $5.6 billion to $6.0 billion, reflecting recent changes in foreign exchange rates.
Investors and analysts are closely monitoring how medical device makers will handle tariffs and whether they expect benefits from foreign currency fluctuations.
Edwards reaffirmed its 2025 adjusted per-share profit of $2.40 to $2.50, taking into account the $1.2 billion deal to buy heart device makers JenaValve and Endotronix, and tariff impact.
The company said it expects pressure on its operating margin as a result of the weakening dollar, the impact of announced tariffs and the expected close of the JenaValve acquisition.
Earlier on Wednesday, larger peer Boston Scientific raised its annual profit forecast, stating strong product demand would counterbalance a potential $200 million hit from tariffs.
Ahead of the earnings, analysts at brokerage J.P.Morgan noted that Edwards is viewed as a “place of relative safety” in the current market environment due to its “lower tariff exposure”.
The company’s manufacturing facilities are located in the United States, Singapore, Costa Rica and Ireland.
Its lead product, the transcatheter aortic valve replacement device (TAVR), is used for minimally invasive heart surgeries.
Sales from the TAVR unit surged by nearly 3.8% to $1.05 billion in the quarter ended March 31, compared with analysts’ average estimate of $1.03 billion, according to data compiled by LSEG.
On an adjusted basis, the medical device maker reported a profit of 64 cents per share, beating analysts’ estimates of 60 cents per share.
For the first quarter, the company reported revenue of $1.41 billion, compared to estimates of $1.40 billion.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Mohammed Safi Shamsi)
Comments